McKesson Corp (MCK) stock
MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3026% above fair value
$1102.81+25.76 (+2.39%)
Close on Nov 13, 2026Market cap $128.58BP/E 28.4Yield 0.29%
McKesson ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
McKesson's ebitda for the twelve months ending Sep 30, 2026 was $7.03B, up 26.8% year over year. For fiscal 2026 it was $6.50B, up 38.5% from the year before. Over ten years it grew 3.9% a year on average. The highest annual figure on record is $8.03B in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $6.50B | +38.5% |
| FY2025 | Mar 31, 2025 | $4.69B | +12.1% |
| FY2024 | Mar 31, 2024 | $4.19B | -10.0% |
| FY2023 | Mar 31, 2023 | $4.65B | +98.0% |
| FY2022 | Mar 31, 2022 | $2.35B | – |
| FY2021 | Mar 31, 2021 | -$4.70B | -266.3% |
| FY2020 | Mar 31, 2020 | $2.82B | +134.7% |
| FY2019 | Mar 31, 2019 | $1.20B | -29.8% |
| FY2018 | Mar 31, 2018 | $1.71B | -78.7% |
| FY2017 | Mar 31, 2017 | $8.03B | +81.3% |
| FY2016 | Mar 31, 2016 | $4.43B | +11.2% |
| FY2015 | Mar 31, 2015 | $3.99B | +25.6% |
| FY2014 | Mar 31, 2014 | $3.17B | +8.4% |
| FY2013 | Mar 31, 2013 | $2.93B | +11.9% |
| FY2012 | Mar 31, 2012 | $2.62B | +12.9% |
| FY2011 | Mar 31, 2011 | $2.32B | -6.8% |
| FY2010 | Mar 31, 2010 | $2.49B | +64.7% |
| FY2009 | Mar 31, 2009 | $1.51B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $1.80B | +12.9% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.51B | +26.9% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $1.90B | +38.2% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.81B | +31.2% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.60B | +115.2% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $1.19B | -0.4% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $1.38B | +168.6% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.38B | +134.2% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $741.00M | -13.8% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $1.20B | +38.8% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $513.00M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $588.00M | -36.2% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $860.00M | -7.4% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $863.00M | +171.4% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$966.00M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $922.00M | -13.7% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $929.00M | +95.6% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $318.00M | -63.0% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$690.00M | -113.8% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $1.07B | +3.2% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $475.00M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $860.00M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $4.99B | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $1.04B | – |
See a number that looks wrong?